US House antitrust committee chair slams Apple for App Store fee
by Maria Thomas
Updated Jun 19, 2020
Apple has faced criticism in several markets including in Europe for the App Store fees, with the European Commission this week opening formal antitrust investigations to assess whether Apple's rules for app developers on the distribution of apps via the App Store violate EU competition rules.
The investigations concern in particular the mandatory use of Apple's own proprietary in-app purchase system and restrictions on the ability of developers to inform iPhone and iPad users of alternative cheaper purchasing possibilities outside of apps.
In the US, similar concerns were raised again after its decision to reject future updates for the iOS app of new email service Hey.
Hey is Basecamp's new $99-a-year premium email service. The controversy hit a new high after Hey did not offer a way to sign up and pay in the app itself in order to avoid paying Apple a 30 percent cut of the fee.
"Because of the market power that Apple has, it is charging exorbitant rents -- highway robbery, basically -- bullying people to pay 30 percent or denying access to their market," Cicilline told The Verge in an interview published on Thursday.
Cicilline said that hearing with the chief executives of four major technology platforms – Facebook, Apple, Google and Amazon -- could happen sometime in July.
Related Articles
- Optical Illusion Brain Test: If you have Sharp Eyes Find the Number 442 in 20 Secs
- London-based firm Nothing to release its Phone (2)
- Covid will continue to cause mini-waves, not become seasonal yet: Scientists
- Hackers offering crypto accounts for as low as $30 on darknet
- Reddit's new feature to allow users to share its content on other platforms
- Surgical masks can help kids fight respiratory infections: Study
- LinkedIn's new AI feature to write messages to hiring team
- Microsoft introduces Xbox Game Pass' new Friend Referral programme
- Disbursed over Rs 31 cr in claims to delivery partners in FY22-23: Swiggy
- India emerging as favourable destination for clinical trials: Report